PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27310876-4 2016 We generated calreticulin-null T-lymphoblasts and confirmed the loss of surface calreticulin expression on cells treated with doxorubicin, an ICD inducer. Doxorubicin 126-137 calreticulin Homo sapiens 80-92 34859582-6 2022 As compared with naive drug, ER-targeted DOX considerably alters the mode of action from nuclear DNA damage-associated cytotoxicity to ER stress-mediated calreticulin exposure. Doxorubicin 41-44 calreticulin Homo sapiens 154-166 34800147-4 2021 METHODS: We treated OC cells with the chemotherapeutic-doxorubicin (DX) known to induce translocation of CRT to some tumour cell surfaces, with and without the ER stressor-thapsigargin (TG)-and/or an ER stress inhibitor-TUDCA. Doxorubicin 55-66 calreticulin Homo sapiens 105-108 32938586-4 2020 B7-H4 expression inhibits doxorubicin-induced cell death through the suppression of eIF2a phosphorylation required for calreticulin exposure vis-a-vis the cancer cells. Doxorubicin 26-37 calreticulin Homo sapiens 119-131 30221067-3 2018 To this aim, we used the pro-ICD agents mitoxantrone and doxorubicin and found that both agents could induce cell death and stimulate the release/exposure of the strictly required DAMPs in melanoma cells: i) calreticulin (CRT) exposure on the cell membrane; ii) ATP secretion; iii) type I IFNs gene up-regulation and iv) HMGB1 secretion, highlighting no interference by oncogenic BRAF. Doxorubicin 57-68 calreticulin Homo sapiens 208-220 12430184-5 2002 Based on the proteome map, we found that DOX causes a markedly decrease in the levels of three isoforms of heat shock protein 27 (HSP27) whereas the levels of other stress associated proteins including HSP60, calreticulin, and protein disulfide isomerase were not significantly altered in DOX-treated MCF-7 cells. Doxorubicin 41-44 calreticulin Homo sapiens 209-221 32898630-5 2020 In vitro studies showed that combination of laser assisted indocyanine green-mediated photothermal therapy and doxorubicin-mediated chemotherapy effectively eradicated cancer cells and resulted in the highest level of damage-associated molecular pattern presentation (calreticulin, high mobility group box 1, and adenosine triphosphate) compared to the individual treatments alone. Doxorubicin 111-122 calreticulin Homo sapiens 268-280 29844817-5 2018 Low levels of CRT and an overexpression of Ki67 were significantly associated with the stage, histology, and differentiation of the primary surgery without doxorubicin (DOX) neoadjuvant chemotherapy (NAC) patient group and were significantly correlated with a short progression-free survival and the overall survival. Doxorubicin 156-167 calreticulin Homo sapiens 14-17 29844817-5 2018 Low levels of CRT and an overexpression of Ki67 were significantly associated with the stage, histology, and differentiation of the primary surgery without doxorubicin (DOX) neoadjuvant chemotherapy (NAC) patient group and were significantly correlated with a short progression-free survival and the overall survival. Doxorubicin 169-172 calreticulin Homo sapiens 14-17 29844817-7 2018 Low CRT expression and an overexpression of Ki67 were significantly associated with DOX-NAC and the histology (P<0.05) pre-NAC and post-NAC in the DOX-NAC patient group. Doxorubicin 84-87 calreticulin Homo sapiens 4-7 29844817-7 2018 Low CRT expression and an overexpression of Ki67 were significantly associated with DOX-NAC and the histology (P<0.05) pre-NAC and post-NAC in the DOX-NAC patient group. Doxorubicin 150-153 calreticulin Homo sapiens 4-7 29844817-8 2018 Upon treatment of DOX-NAC, CRT, PERK and p-eIF2alpha protein content were overexpressed in DOX-sensitive endometrial cancer (P<0.05), whereas there was no significant difference in the DOX-resistant group. Doxorubicin 18-21 calreticulin Homo sapiens 27-30 29844817-8 2018 Upon treatment of DOX-NAC, CRT, PERK and p-eIF2alpha protein content were overexpressed in DOX-sensitive endometrial cancer (P<0.05), whereas there was no significant difference in the DOX-resistant group. Doxorubicin 91-94 calreticulin Homo sapiens 27-30 29844817-8 2018 Upon treatment of DOX-NAC, CRT, PERK and p-eIF2alpha protein content were overexpressed in DOX-sensitive endometrial cancer (P<0.05), whereas there was no significant difference in the DOX-resistant group. Doxorubicin 91-94 calreticulin Homo sapiens 27-30 29844817-10 2018 CRT may therefore serve as a molecular marker for predicting the progression and prognosis in DOX-resistant endometrial cancer patients. Doxorubicin 94-97 calreticulin Homo sapiens 0-3 27310876-5 2016 Reconstituted expression with full-length calreticulin targeted to the endoplasmic reticulum (ER) successfully rescued doxorubicin-induced surface calreticulin. Doxorubicin 119-130 calreticulin Homo sapiens 42-54 27310876-5 2016 Reconstituted expression with full-length calreticulin targeted to the endoplasmic reticulum (ER) successfully rescued doxorubicin-induced surface calreticulin. Doxorubicin 119-130 calreticulin Homo sapiens 147-159 27310876-6 2016 Reconstitution with a truncation mutant calreticulin targeted to the cytosol led to constitutively high surface calreticulin that was not further elevated by doxorubicin, suggesting calreticulin released from the stressed ER transits the cytosol before its translocation to the cell surface. Doxorubicin 158-169 calreticulin Homo sapiens 40-52 27310876-7 2016 When stimulated to engage integrin substrates, doxorubicin-treated wild-type T-lymphoblasts exhibited decreased surface calreticulin compared with cells under non-adherent conditions. Doxorubicin 47-58 calreticulin Homo sapiens 120-132 20716130-2 2011 Doxorubicin also induces the translocation on the plasma membrane of the protein calreticulin (CRT), which allows tumour cells to be phagocytized by dendritic cells. Doxorubicin 0-11 calreticulin Homo sapiens 81-93 20716130-2 2011 Doxorubicin also induces the translocation on the plasma membrane of the protein calreticulin (CRT), which allows tumour cells to be phagocytized by dendritic cells. Doxorubicin 0-11 calreticulin Homo sapiens 95-98 20716130-3 2011 We have shown that doxorubicin elicits nitric oxide synthesis and CRT exposure only in drug-sensitive cells, not in drug-resistant ones, which are indeed chemo-immunoresistant. Doxorubicin 19-30 calreticulin Homo sapiens 66-69 20716130-5 2011 In the drug-sensitive colon cancer HT29 cells doxorubicin increased nitric oxide synthesis, CRT exposure and cells phagocytosis. Doxorubicin 46-57 calreticulin Homo sapiens 92-95 20716130-7 2011 CRT translocation did not occur in drug-resistant HT29-dx cells, where the doxorubicin-induced nitric oxide synthesis was absent. Doxorubicin 75-86 calreticulin Homo sapiens 0-3 20716130-8 2011 By increasing nitric oxide with stimuli other than doxorubicin, the CRT exposure was obtained also in HT29-dx cells. Doxorubicin 51-62 calreticulin Homo sapiens 68-71